Skip to content

Guardant Health GH Free cash flow

Free cash flow at other companies

NeoGenomics logo
NeoGenomicsNEO
-$13.14M+56.0%
Veracyte logo
VeracyteVCYT
$32.25M+810%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$10.25M-18.1%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$10.33M+65.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$25.67M-25.4%
Illumina logo
IlluminaILMN

Other financials

Income statement

See full
Revenue$301.7M+48.3%
Gross profit$196.7M+52.8%
Operating income-$121.4M-9.3%
Net income-$112.1M-17.8%
EPS (diluted)-$0.85-10.4%

Balance sheet

See full
Cash & equivalents$1.1B+37.0%
Total debt$1.7B+30.5%
Total equity-$181.1M+27.8%
Total assets$1.9B+42.5%

Cash flow

See full
Operating cash flow-$65.6M-4.7%
CapEx$5.6M+25.1%

Valuation

See full
Market cap$19.92B+253%
Enterprise value$20.52B+229%
P/S18.4×+11.6×

Profitability

See full
Gross margin64.9%+3.6pp
Operating margin-41.4%-9.4pp
Net margin-40.1%-8.1pp
FCF margin-22%-6.7pp

Returns & leverage

See full
Return on equity-438.1%-1,655pp
Debt / equity
Current ratio4.7×+0.6×

Where this comes from

Calculated from Guardant Health’s reported figures.

The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardant Health's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardant Health's free cash flow?
Guardant Health (GH) reported free cash flow of -$71.2M in Q1 2026.
How has Guardant Health's free cash flow changed year-over-year?
Guardant Health's free cash flow decreased by 6.0% year-over-year, from -$67.15M to -$71.2M.
What is the long-term trend for Guardant Health's free cash flow?
Over 4 years (2021 to 2025), Guardant Health's free cash flow has grown at a -4.8% compound annual growth rate (CAGR), from -$284.05M to -$233.07M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.